ADRB2 and metabolic syndrome: It is also possible that the β1-AR blockage may result in the preferential activation of β2-AR, explaining why BB treatment is associated with an increased incidence of dyslipidemia in patients with this variant (Iaccarino et al., 2005; Isaza et al., 2007).